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Background:  A  recent  study  showed  that  a high-dose  inactivated  inﬂuenza  vaccine  (IIV-HD)  was 24.2%
more  efﬁcacious  than  a standard-dose  inactivated  inﬂuenza  vaccine  (IIV-SD)  in  preventing  laboratory-
conﬁrmed  symptomatic  inﬂuenza  in adults ≥65 years.  Here  we  evaluate  the effectiveness  of  IIV-HD
compared  to IIV-SD  in  preventing  serious  illnesses  considered  potential  sequelae  or complications  of
inﬂuenza  infection.
Methods:  The  original  study  was  a double-blind,  randomized,  active-controlled,  multicenter  trial.  Par-
ticipants  were  adults  ≥65  years  randomized  to receive  IIV-HD  or IIV-SD,  and  followed  for 6–8 months
post-vaccination  for the  occurrence  of  inﬂuenza  and  serious  adverse  events  (SAEs).  SAEs  were  events:
leading  to  death  or hospitalization  (or  its prolongation);  considered  life-threatening  or  medically  impor-
tant; or  resulting  in  disability.  For  the  present  analysis,  reported  SAEs  were  classiﬁed  as  possibly  related
to  inﬂuenza  by  three  blinded  physicians  and rates  per 1000  participant-seasons  were  calculated.  Relative
vaccine  effectiveness  (rVE)  was  estimated  as (1  − Rate  Ratio)  ×  100.
Results:  31,989  participants  were  enrolled,  with 15,991  and  15,998  randomized  to receive  IIV-HD  and  IIV-
SD, respectively.  IIV-HD  was  signiﬁcantly  more  effective  than  IIV-SD  in preventing  SAEs  possibly  related
to  inﬂuenza  overall  (rVE,  17.7%;  95% conﬁdence  interval  [CI],  6.6–27.4%)  and  serious  pneumonia  (rVE,
39.8%;  95%  CI,  19.3–55.1%).  Borderline  signiﬁcance  was  observed  for the  efﬁcacy  of IIV-HD  relative  to
IIV-SD  for the  prevention  of all-cause  hospitalizations  (rVE,  6.9%;  95%  CI, 0.5–12.8%).
Conclusions:  Compared  to IIV-SD,  IIV-HD  reduced  the  risk  of  SAEs  possibly  related  to  inﬂuenza.  The
observed  relative  effectiveness  against  serious  pneumonia  is particularly  noteworthy  considering  the
burden  of  inﬂuenza  and  pneumonia  in  older  adults.
ublis©  2015  The  Authors.  P
. IntroductionAdults 65 years of age and older are particularly vulnerable
o complications from inﬂuenza infection, accounting for most
Abbreviations: IIV-HD, high-dose inactivated inﬂuenza vaccine; CI, conﬁdence
nterval; IIV-SD, standard-dose inactivated inﬂuenza vaccine; SAE, serious adverse
vent; COPD, chronic obstructive pulmonary disease; RR, rate ratios; rVE, relative
accine effectiveness; FAS, Full Analysis Set; ITT, intent-to-treat; CAP, community-
cquired pneumonia.
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DOI: http://dx.doi.org/10.1016/j.jamda.2013.12.076).
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uhed  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
seasonal inﬂuenza-related hospitalizations and deaths [1,2]. The
high burden of inﬂuenza in this population persists despite docu-
mented improvements in vaccination rates [3]. Accordingly, the
availability of improved inﬂuenza vaccines for older adults had
been considered an unmet medical need [4,5]. A recently completed
double-blind, randomized, controlled trial (NCT01427309) demon-
strated that a high-dose inactivated inﬂuenza vaccine (IIV-HD) was
24.2% (95% conﬁdence interval [CI], 9.7%–36.5%) more efﬁcacious
than a standard-dose inactivated inﬂuenza vaccine (IIV-SD) in pre-
venting laboratory-conﬁrmed symptomatic inﬂuenza in adults 65
years of age and older [6].In addition to the observed improvement in efﬁcacy, 119 fewer
study participants developed at least one serious adverse event
(SAE) of any cause in the IIV-HD group compared to the IIV-SD
group. The risk of developing at least one SAE during the study was
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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igniﬁcantly lower among IIV-HD recipients than IIV-SD recipients
relative risk 0.92, 95% CI, 0.85–0.99), suggesting that IIV-HD may
mprove protection against the occurrence of inﬂuenza-related
erious events [6].
According to results from the last National Hospital Discharge
urvey conducted by the National Center for Health Statistics in the
nited States, the top leading causes of hospitalization in adults 65
ears or older are heart disease (including ischemic heart disease
nd congestive heart failure), cerebrovascular disease, pneumonia,
nd malignant neoplasms [7]. Excluding malignancy, inﬂuenza may
lay an important role in the occurrence of these hospitalization-
elated events, either by triggering exacerbations of pre-existing
onditions or by direct involvement of affected organs or tissues
8–13]. It is therefore of particular interest for individual and public
ealth to evaluate the impact of inﬂuenza vaccines on the occur-
ence of serious cardio-respiratory events traditionally considered
otential complications or sequelae of inﬂuenza. To this end, the
resent supplementary analysis of the original efﬁcacy trial evalu-
ted the effectiveness of IIV-HD compared to IIV-SD in preventing
ll-cause hospitalizations and serious cardio-respiratory events
ossibly related to inﬂuenza infection.
. Methods
.1. Overall study design
Details of the original study design are presented else-
here [6]. Brieﬂy, the study was a double-blind, randomized,
ctive-controlled, multicenter clinical trial, conducted during the
011–2012 (Year 1) and 2012–2013 (Year 2) inﬂuenza seasons in
26 research centers in the United States and Canada. Adults 65
ears of age and older were randomly assigned in a 1:1 ratio to
eceive IIV-HD (Fluzone® High-Dose [Sanoﬁ Pasteur, Swiftwater,
A, USA], containing 60 g of hemagglutinin per vaccine strain) or
IV-SD (Fluzone [Sanoﬁ Pasteur, Swiftwater, PA, USA], containing
5 g of hemagglutinin per strain). Each season, participants were
ollowed for 6–8 months post-vaccination for the occurrence of
nﬂuenza and SAEs. SAEs were deﬁned as events: leading to death or
ospitalization (or its prolongation); considered as life-threatening
r medically important; or resulting in disability [14]. Based on
vailable medical information, study investigators reported the
iagnoses associated with all SAEs.
.2. Adjudication of SAEs as “serious events possibly related to
nﬂuenza”
Two physicians blinded to treatment group independently
eviewed all SAE diagnostic categories that were reported during
he study; these diagnostic categories had been coded as “preferred
erms” using the Medical Dictionary for Regulatory Activities [15]
ersions 14.0 (for Year 1) and 15.0 (for Year 2) before study unblind-
ng. There were a total of 1347 SAE preferred terms reviewed.
ardio-respiratory SAE categories considered as possibly related to
nﬂuenza infection were selected by each reviewer, based solely on
he medical nature of the reported preferred term for the diagnosis
for example, SAEs with a diagnosis preferred term of “pneumo-
ia” were selected as possibly related to inﬂuenza, whereas SAEs
ith a diagnosis preferred term of “hip fracture” were excluded).
he physician-reviewers then compared their respective selections
nd exclusions to attempt consensus, which was attained for 1335
99.1%) SAE preferred terms. The 12 remaining discrepant SAE
referred term categorizations were arbitrated by a third blinded
hysician-reviewer. Final adjudication of SAE categories as “possi-
ly related to inﬂuenza” was done before study unblinding, and
he selected categories were pre-speciﬁed in a supplementaryne 33 (2015) 4988–4993 4989
analysis plan. Adjudication was done without regard to inﬂuenza
conﬁrmation in the study. Events were grouped in seven larger
categories: pneumonia events, asthma/COPD (chronic obstructive
pulmonary disease)/bronchial events, inﬂuenza events (serious
laboratory-conﬁrmed inﬂuenza diagnosed outside study proce-
dures by a participant’s health-care provider), other respiratory
events, coronary artery events, congestive heart failure events, and
cerebrovascular events. The selected preferred terms and their clas-
siﬁcation are available in Supplementary appendix. All preferred
terms for the SAEs reported in the study (selected and not selected)
are publicly available at clinicaltrials.gov [16].
2.3. Statistical methods
Rates of all-cause hospitalizations and selected serious cardio-
respiratory events were calculated for IIV-HD and IIV-SD groups
as the number of hospitalizations or events per 1000 participant-
seasons. Rate ratios (RRs) and corresponding 2-sided 95% CIs were
estimated using the method given by Blackwelder [17]. Relative
vaccine effectiveness (rVE) was  calculated as (1 − RR) × 100.
Analyses were done in the Full Analysis Set (FAS) according to
the vaccine assigned at randomization (intent-to-treat [ITT] analy-
sis). The FAS comprised all participants who  received study vaccine.
Estimates were obtained for each study season and for both sea-
sons combined. Statistical signiﬁcance was  deﬁned as a 2-sided 95%
CI excluding the null value (1 for RR and 0 for rVE).
3. Results
A total of 31,989 participants were enrolled in the study, of
whom 15,991 were randomized to IIV-HD (15,990 included in
the ITT analysis) and 15,998 were randomized to IIV-SD (15,993
included in the ITT analysis). Only 24 participants did not receive
the vaccine as randomized (0.08%). Enrollees included 14,500 par-
ticipants in Year 1 and 17,489 in Year 2.
Baseline clinical and demographic characteristics were well bal-
anced between groups [6]. In both groups, the mean age was
73.3 years, 56–57% of participants were female, approximately
67% had at least one high-risk pre-speciﬁed comorbid illness, and
approximately 74% had received inﬂuenza vaccination the previ-
ous season. The frequency of historical pneumococcal vaccination
prior to study start was  essentially the same for IIV-HD (65.17%)
and IIV-SD (64.81%) recipients. Pneumococcal vaccination during
the study was rare, and of approximate equal frequency between
groups (3.57% for IIV-HD, 3.53% for IIV-SD). Study mean participant
follow-up time was  226 days for both groups.
There were a total of 3173 hospitalization events (all-cause),
1590 in Year 1 and 1583 in Year 2. The number and rate of occur-
rence of all SAEs reported in the study (selected and not selected
for this supplementary analysis) by treatment group and study year
are available at clinicaltrials.gov [16].
A total of 948 serious cardio-respiratory events adjudicated as
possibly related to inﬂuenza were reported in the study, 440 in Year
1 and 508 in Year 2. The vast majority of these cardio-respiratory
events resulted in hospitalization (94.8%) and a smaller proportion
were fatal (6.9%).
Rates of all-cause hospitalizations and serious cardio-
respiratory events possibly related to inﬂuenza (overall and
by category) for IIV-HD and IIV-SD are presented in Table 1.
Corresponding RRs and CIs are depicted graphically in Fig. 1.
Rates of all-cause hospitalization did not differ between groups
in Year 1, whereas they were signiﬁcantly lower for the IIV-HD
group in Year 2; for both study years combined, the rate of all-cause
hospitalization was  6.9% (95% CI, 0.5–12.8%) lower in the IIV-HD
group.
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Table 1
Rates of all-cause hospitalization and serious cardio-respiratory events possibly related to inﬂuenza (intent-to-treat analysis).
Year 1 Year 2 Combined
IIV-HD
(N = 7253),
n  (rate)a
IIV-SD (N = 7244),
n  (rate)a
IIV-HD
(N = 8737),
n (rate)a
IIV-SD (N = 8749),
n (rate)a
IIV-HD
(N = 15,990),
n  (rate)a
IIV-SD
(N = 15,993),
n  (rate)a
All-cause hospitalization 797 (109.89) 793 (109.47) 733 (83.90) 850 (97.15) 1530 (95.68) 1643 (102.73)
Serious cardio-respiratory events 204 (28.13) 236 (32.58) 224 (25.64) 284 (32.46) 428 (26.77) 520 (32.51)
Pneumonia events 29 (4.00) 54 (7.45) 42 (4.81) 64 (7.32) 71 (4.44) 118 (7.38)
Asthma/COPD/bronchial events 40 (5.51) 21 (2.90) 34 (3.89) 54 (6.17) 74 (4.63) 75 (4.69)
Inﬂuenza eventsb 1 (0.14) 0 (0.00) 3 (0.34) 6 (0.69) 4 (0.25) 6 (0.38)
Coronary artery events 55 (7.58) 70 (9.66) 66 (7.55) 54 (6.17) 121 (7.57) 124 (7.75)
Congestive heart failure 24 (3.31) 28 (3.87) 33 (3.78) 47 (5.37) 57 (3.56) 75 (4.69)
Cerebrovascular events 43 (5.93) 39 (5.38) 29 (3.32) 38 (4.34) 72 (4.50) 77 (4.81)
Other  respiratory events 13 (1.79) 24 (3.31) 18 (2.06) 23 (2.63) 31 (1.94) 47 (2.94)
Abbreviations:  IIV-HD, high-dose inactivated inﬂuenza vaccine; IIV-SD, standard-dose inactivated inﬂuenza vaccine; COPD, chronic obstructive pulmonary disease
a n = number of events; rate = events per 1000 participant-seasons.
b Corresponding to serious laboratory-conﬁrmed inﬂuenza diagnosed outside study procedures by a participant’s health-care provider.
Rate Ratio (95% CI)
YEAR 1 
All-cause  hosp italization 1.00 (0.91 ; 1.10) 
Serious cardio-respiratory events 0.86 (0.72 ; 1.04) 
    Pneumonia events 0.54 (0.34; 0.84) 
    Asthma/COPD/bronch ial events 1.90 (1.12; 3.22) 
    Influenza ev ents  NA 
    Coronary artery events 0.78 (0.55; 1.12) 
    Congestive heart failure  0.86 (0.50 ; 1.48) 
    Cerebrova scular event s 1.10 (0.71 ; 1.70) 
    Other  respiratory  even ts 0.54 (0.28 ; 1.06) 
YEAR 2 
All-cause  hosp italization 0.86 (0.79 ; 0.95) 
Serious cardio-respir atory even ts 0.79 (0.66 ; 0.94) 
    Pneumoni a events 0.66 (0.45 ; 0.97) 
    Asthma/COPD/bronch ial events 0.63 (0.41 ; 0.97) 
    Influenza ev ents  0.50 (0.13 ; 2.00) 
    Coronary artery events 1.22 (0.86 ; 1.75) 
    Congestive heart failure 0.70 (0.45 ; 1.10) 
    Cerebrova scular event s 0.76 (0.47 ; 1.24) 
    Other  respiratory  even ts 0.78 (0.42 ; 1.45) 
COMBINED (YEAR  1 AND YE AR 2) 
All-cause  hosp italization 0.93 (0.87 ; 1.00) 
Serious cardio-respir atory even ts 0.82 (0.73 ; 0.93) 
    Pneumoni a events 0.60 (0.45 ; 0.81) 
    Asthma/COPD/bronch ial events 0.99 (0.72 ; 1.36) 
    Influenza ev ents  0.67 (0.19 ; 2.36) 
    Coronary artery events 0.98 (0.76 ; 1.25) 
    Congestive heart failure  0.76 (0.54 ; 1.07) 
    Cerebrova scular event s 0.94 (0.68 ; 1.29) 
    Other  respiratory  even ts 0.66 (0.42 ; 1.04) 
         < < Favors IIV-HD    Favors IIV-SD > >
.13 .2 5 .5 1 2 4
Fig. 1. Rate ratios (IIV-HD/IIV-SD) for all-cause hospitalization and serious cardio-respiratory events possibly related to inﬂuenza (intent-to-treat analysis). Each horizontal
line  represents the 95% conﬁdence interval of the rate ratio for each comparison, with the center being the corresponding point estimate. The vertical line represents the null
value  of 1. Horizontal lines that do not intersect with the vertical line are statistically signiﬁcant. Point estimates to the left of vertical line favor IIV-HD, and those to the right
favor  IIV-SD. “Inﬂuenza Events” refer to serious laboratory-conﬁrmed inﬂuenza diagnosed outside study procedures by a participant’s health-care provider. Abbreviations:
IIV-HD,  high-dose inactivated inﬂuenza vaccine; IIV-SD, standard-dose inactivated inﬂuenza vaccine; COPD: chronic obstructive pulmonary disease.
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Table  2
Effectiveness of IIV-HD relative to IIV-SD against all-cause hospitalization and serious cardio-respiratory events possibly related to inﬂuenza (intent-to-treat analysis).
Year 1
N = 14,497,
rVE% (95% CI)
Year 2
N = 17,486,
rVE% (95% CI)
Combined
N = 31,983,
rVE% (95% CI)
All-cause hospitalization −0.4 (−10.1; 8.5) 13.6 (5.1; 21.4) 6.9 (0.5; 12.8)
Serious cardio-respiratory events 13.7 (−3.8; 28.2) 21.0 (6.1; 33.5) 17.7 (6.6; 27.4)
Pneumonia events 46.4 (15.9; 65.8) 34.3 (3.1; 55.4) 39.8 (19.3; 55.1)
Asthma/COPD/bronchial events −90.2 (−222.3; −12.3) 37.0 (3.3; 58.9) 1.3 (−36.0; 28.4)
Inﬂuenza eventsa NE 49.9 (−100.1; 87.5) 33.3 (−136.2; 81.2)
Coronary artery events 21.5 (−11.5; 44.8) −22.4 (−75.1; 14.5) 2.4 (−25.3; 24.0)
Congestive heart failure 14.4 (−47.5; 50.3) 29.7 (−9.6; 54.9) 24.0 (−7.2; 46.1)
Cerebrovascular events −10.1 (−69.7; 28.5) 23.6 (−23.8; 52.8) 6.5 (−28.9; 32.1)
Other  respiratory events 45.9 (−6.2; 72.4) 21.6 (−45.1; 57.7) 34.0 (−3.8; 58.1)
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a Corresponding to serious laboratory-conﬁrmed inﬂuenza diagnosed outside stu
For the 2 study years combined, the aggregate rates of seri-
us cardio-respiratory events possibly related to inﬂuenza were
ower in the IIV-HD group for any event overall and for each of the
even pre-speciﬁed categories. For each of the 2 study years, con-
istently lower rates in the IIV-HD group were observed for any
erious cardio-respiratory event possibly related to inﬂuenza over-
ll, serious pneumonia, serious congestive heart failure, and other
erious respiratory events (i.e., selected respiratory diagnoses other
han pneumonia, asthma/COPD/bronchial events, or inﬂuenza; see
upplementary appendix for details).
Signiﬁcantly lower rates in the IIV-HD group were observed for:
ny serious cardio-respiratory event possibly related to inﬂuenza
verall in Year 2 and both years combined; serious pneumo-
ia in each study year and the 2 years combined; and serious
sthma/COPD/bronchial events in Year 2. A signiﬁcantly lower rate
or IIV-SD compared to IIV-HD was observed only for the occurrence
f serious asthma/COPD/bronchial events in Year 1.
Point estimates and 95% CIs for the effectiveness of IIV-HD com-
ared to IIV-SD for the prevention of all-cause hospitalization and
erious cardio-respiratory events possibly related to inﬂuenza are
resented in Table 2. The largest reduction in disease burden was
bserved for serious pneumonia, which was reported 39.8% less
requently among IIV-HD recipients than among IIV-SD recipients
verall (both years combined): 46.4% in Year 1 and 34.3% in Year 2.
ll three measures of rate reduction for serious pneumonia were
tatistically signiﬁcant (p values 0.001, 0.006, and 0.040 for both
ears combined, Year 1 and Year 2, respectively).
. Discussion
Inﬂuenza is associated with high morbidity and mortality in
lder adults [4]. Although vaccination currently represents the
ost effective intervention in preventing inﬂuenza and its com-
lications [2,18], antibody responses and protection elicited by
tandard-dose inﬂuenza vaccines are lower in persons 65 years
f age and older compared to younger adults [19–21]. Strategies
o improve immune responses to inﬂuenza vaccines in this pop-
lation may  have a favorable impact on morbidity and mortality
22]. Several approaches have been developed to improve immune
esponses to inﬂuenza in older adults, including the use of higher
oses of antigen, adjuvants [23–26], and alternative delivery sys-
ems [27]. One of such approaches is IIV-HD, which contains four
imes the amount of hemagglutinin antigen per strain compared to
tandard-dose intramuscular inﬂuenza vaccines.
Because of the recognized association of inﬂuenza with seri-
us illness in older adults, we explored the impact of IIV-HD
eyond its demonstrated superior efﬁcacy over IIV-SD in preven-
ing laboratory-conﬁrmed inﬂuenza illness, by evaluating IIV-HD
ffectiveness in preventing hospitalization and serious illness pos-
ibly related to inﬂuenza. To achieve this objective, we performed abstructive pulmonary disease; NE, non-evaluable.
ocedures by a participant’s health-care provider.
supplementary analysis of data collected during the original large-
scale efﬁcacy study.
We  observed that IIV-HD was signiﬁcantly more effective than
IIV-SD in preventing serious cardio-respiratory events possibly
related to inﬂuenza, most of which corresponded to hospitaliza-
tions, with an overall relative vaccine effectiveness of 17.7%. Two
recently published studies have evaluated the effect of IIV-HD
compared to IIV-SD on similar outcomes: consistent with our ﬁnd-
ings, a large retrospective cohort study [28] reported an overall
relative effectiveness estimate of 20.6% against inﬂuenza hospital
admissions or emergency department visits, with similar estimates
observed for individuals 65–74 years, 75–84 years, and ≥85 years;
in contrast, another retrospective cohort study found evidence of
improved effectiveness of IIV-HD against inﬂuenza and pneumonia
hospitalizations only in individuals ≥85 years of age [29]. Com-
pared to previous reports, our results have the major strength of
resulting from a large double-blind, randomized, controlled trial,
which minimizes the likelihood of bias, including the so-called
healthy vaccinee bias [30,31]. Moreover, we observed a borderline
signiﬁcant overall effectiveness of IIV-HD relative to IIV-SD for the
prevention of all-cause hospitalization.
As the original study was  only powered to evaluate the pri-
mary endpoint of laboratory-conﬁrmed inﬂuenza associated with a
protocol-deﬁned inﬂuenza-like illness, the present supplementary
analysis cannot be expected to reveal all true effects with statisti-
cal signiﬁcance. Therefore, an important aspect for the evaluation
of a possible causal association between IIV-HD and prevention
of serious cardio-respiratory events compared to IIV-SD is the
reproducibility of the results under independent observations. The
efﬁcacy study was  performed over 2 years characterized by dis-
tinct inﬂuenza seasons: the ﬁrst had low inﬂuenza activity and was
characterized by moderate to good match between the vaccine and
circulating strains; the second had high inﬂuenza activity and was
characterized by mismatch between the predominant circulating
inﬂuenza virus strain and the vaccine strains. Because of the het-
erogeneity of the two  inﬂuenza study seasons, the consistency of
the association between IIV-HD and prevention of serious events
could be evaluated based on these two  independent sets of data.
Rates of serious events were consistently lower for IIV-HD than for
IIV-SD in both study years for three of the seven pre-selected seri-
ous cardio-respiratory event categories (pneumonia, other selected
respiratory events, and heart failure) and for the aggregate occur-
rence of any serious event possibly related to inﬂuenza. Moreover,
the various point estimates (Fig. 1) were nearly all arrayed in favor
of IIV-HD, demonstrating an important consistency of results.
It is well-established that inﬂuenza can cause primary viral
pneumonia and predispose infected individuals to secondary bac-
terial pneumonia [13,32]. Community-acquired pneumonia (CAP)
is a major cause of morbidity and mortality in older adults, with
915,900 episodes estimated to occur annually in the United States
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n adults 65 years of age and older [33]. Pneumonia is the third
eading cause of hospitalization and sixth leading cause of death
n older adults [7,34]. Strategies to prevent CAP have targeted
treptococcus pneumoniae, which is the major bacterial pathogen
ssociated with this illness. Two vaccines are currently licensed in
he United States for the prevention of pneumococcal disease in
lder adults: 23-valent pneumococcal polysaccharide vaccine and
3-valent pneumococcal conjugate vaccine. Although the polysac-
haride vaccine is considered efﬁcacious in preventing invasive
neumococcal disease in older adults [35], its role in the preven-
ion of non-bacteremic CAP has been a matter of debate [36]. The
3-valent pneumococcal conjugate vaccine recently demonstrated
igniﬁcant efﬁcacy in the prevention of invasive pneumococcal dis-
ase and pneumococcal pneumonia due to included serotypes in a
andomized placebo-controlled trial conducted in the Netherlands
mong approximately 85,000 adults aged ≥65 years [37]. The study
howed 45.6% efﬁcacy against vaccine-type pneumococcal pneu-
onia. In this context, the observed 39.8% overall effectiveness of
IV-HD compared to IIV-SD against serious pneumonia of any etiol-
gy in our study is particularly noteworthy. Moreover, IIV-HD effec-
iveness against serious pneumonia was consistent and statistically
igniﬁcant in each of the two study years. Previous reports have also
ignaled a favorable impact of inﬂuenza vaccines on CAP [25,38].
A recent meta-analysis of randomized controlled trials reported
hat the use of inﬂuenza vaccines was associated with a lower risk of
ajor adverse cardiovascular events (cardiovascular death or hos-
italization associated with myocardial infarction, unstable angina,
troke, heart failure, or urgent coronary revascularization) [39]. We
bserved 24.0% overall effectiveness of IIV-HD over IIV-SD against
erious congestive heart failure. Of note, although not statistically
igniﬁcant, positive relative effectiveness point estimates (favor-
ng IIV-HD) for preventing serious heart failure were consistently
bserved in both years of the study. This was not the case for serious
oronary and cerebrovascular events, for which the relative effec-
iveness estimates were imprecise and variable across study years.
The interpretation of the results for serious asthma/COPD/
ronchial events and all-cause hospitalization in our study is chal-
enging: the rate of asthma/COPD/bronchial events for IIV-HD
ecipients was signiﬁcantly higher than the rate for IIV-SD recipi-
nts in Year 1 of the study, but signiﬁcantly lower in Year 2; and the
ate of all-cause hospitalization events for IIV-HD recipients was
he same as the rate for IIV-SD recipients in Year 1 of the study,
igniﬁcantly lower for the IIV-HD group in Year 2, and also lower
or the IIV-HD group with borderline statistical signiﬁcance for both
ears combined. The apparent disparate estimates from year to year
or these outcomes may  be explained by the large differences in the
pidemiology of the two inﬂuenza seasons encompassing the study,
he role that inﬂuenza may  have played in triggering new onset or
xacerbations of bronchial events and any hospitalization, and the
act that evaluated outcomes in this supplementary analysis did not
equire laboratory conﬁrmation of inﬂuenza. Since the ﬁrst year of
he study coincided with very low inﬂuenza activity [40], and the
econd year of the study coincided with very high inﬂuenza activ-
ty [41], it is conceivable that the majority of bronchial events and
ospitalizations in Year 1 of the study may  have been unrelated to
nﬂuenza and therefore unlikely to be affected by a more efﬁcacious
nﬂuenza vaccine. Given the higher level of inﬂuenza activity dur-
ng the second year of the study, it is likely that the proportion of
nﬂuenza-related bronchial events and hospitalizations increased
eaningfully in Year 2, revealing a possible protective effect from
IV-HD over IIV-SD. Therefore, while investigating inﬂuenza vac-
ine effects, the inﬂuenza speciﬁcity of the bronchial and all-cause
ospitalization events might have been higher in the second year of
he study than in the ﬁrst year. It has been well established that the
se of non-speciﬁc outcomes can affect efﬁcacy/effectiveness esti-
ates by biasing them towards the null [42]. While this can explainne 33 (2015) 4988–4993
null estimates for hospitalization in Year 1, it may  not completely
explain the observed signiﬁcantly higher rate of bronchial events
in the IIV-HD arm in Year 1. In our view, the most likely explana-
tion for this observation is random error in the context of multiple
comparisons.
It is also interesting that while the analyses showed that IIV-HD
was not effective in preventing serious bronchial events in Year 1,
it showed strong effectiveness of the vaccine against serious pneu-
monia during the same period. This suggests that the observed
serious pneumonia events may  have been more likely to be asso-
ciated with inﬂuenza than the observed serious bronchial events,
making the pneumonia outcomes more speciﬁc than the bronchial
outcomes and therefore less likely to be negatively biased. How-
ever, the fact that strong effectiveness against serious pneumonia
was observed in the context of a weak inﬂuenza season in Year
1 of the study suggests that IIV-HD may  have ancillary effects on
the most common etiologies of serious pneumonia (beyond its pre-
vention or modulation of inﬂuenza), mediated directly through a
cross-pathogen immune response or indirectly through alterations
of the nasopharyngeal microbiome. These interpretations remain
speculative at this time and further research is required to test them
as formal hypotheses.
This supplementary analysis of the original study has several
limitations. As mentioned earlier, the original study was not pow-
ered to address the objectives of this analysis, and the outcomes
evaluated here were not necessarily inﬂuenza-speciﬁc. These two
factors likely affected both the magnitude and precision of the
observed effects. In addition, the study compared IIV-HD with IIV-
SD, an active control that likely provided some protective effects
against the evaluated outcomes. Accordingly, the supplementary
analysis may underestimate the effect that IIV-HD may  have on
the prevention of serious cardio-respiratory events. Finally, this
analysis evaluated multiple associations without correcting for
multiplicity. Therefore, even statistically signiﬁcant effects need to
be interpreted with caution.
In conclusion, this supplementary analysis suggests that
compared to IIV-SD, IIV-HD may better prevent serious cardio-
respiratory illnesses considered potential sequelae or complica-
tions of inﬂuenza infection. The observed effectiveness against
serious pneumonia is particularly noteworthy considering the dis-
proportionate burden of inﬂuenza and pneumonia in older adults.
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